DEF: USANA Health Sciences Schedules 2026 Annual Meeting

USANA Health Sciences announces its 2026 Annual Meeting of Shareholders, to be held virtually on May 20, 2026, with key proposals including director elections and executive compensation.

Summary

• USANA Health Sciences, Inc. is holding its 2026 Annual Meeting of Shareholders on Wednesday, May 20, 2026, at 11:00 AM Mountain Daylight Time.
• The meeting will be conducted entirely via a live webcast, with no in-person attendance option.
• Shareholders can participate and vote electronically by visiting www.virtualshareholdermeeting.com/USNA2026 using a provided 16-digit control number.
• The agenda includes the election of eight directors, ratification of KPMG LLP as the independent registered public accounting firm for Fiscal Year 2026, and an advisory vote to approve executive compensation.
• The record date for eligibility to vote is March 16, 2026.
• Proxy materials are being made available electronically via the Internet, with a Notice of Internet Availability mailed on April 7, 2026.
• The company emphasizes the importance of shareholder participation and voting, offering options via Internet, telephone, or mail.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance practices and a routine annual meeting announcement. While there are no significant negative financial disclosures, the decline in core nutritional sales and the conditional nature of future incentive awards temper a more optimistic outlook.

Positives

• The company is leveraging electronic distribution of proxy materials to reduce costs and environmental impact.
• A virtual meeting format allows for global shareholder participation.
• The Board of Directors is committed to sound corporate governance principles, with a majority of independent directors.
• Stock ownership requirements are in place for directors and executive officers to align interests with shareholders.
• The company has a clawback policy to recoup excess incentive compensation in case of accounting restatements.
• The Audit Committee has determined that key members qualify as audit committee financial experts.
• The Compensation Committee ensures that compensation programs do not encourage excessive risk-taking.
• Shareholder support for executive compensation was over 95% at the 2025 Annual Meeting.

Negatives

• The company experienced an 8.0% decrease in core nutritional net sales in Fiscal Year 2025 compared to Fiscal Year 2024.
• Performance conditions for 2023 PSUs were not met, leading to their cancellation in February 2026.
• The company's CEO pay ratio of 85:1, while within SEC rules, highlights a significant compensation disparity.
• The Tax Cuts and Jobs Act limits the deductibility of executive compensation exceeding $1 million.

Risks

• The company's core nutritional business experienced a sales decrease in Fiscal Year 2025.
• The effectiveness of the 2026 PSU Award is contingent on achieving specific market conditions and outperforming the Russell 2000 Index.
• The company's executive compensation is subject to Section 162(m) of the Internal Revenue Code, limiting deductibility.
• The company's reliance on direct selling models may be subject to evolving market dynamics and regulatory scrutiny.
• Operational risks related to information technology systems, including data security, data privacy, and AI matters, are overseen by the Governance, Risk & Nominating Committee.

Future Outlook

The company expects that enhancements to its Brand Partner compensation plan will benefit the business in 2026 through increased sales force engagement and productivity. The company is confident that its diversification strategy towards an omnichannel model will lay the foundation for long-term growth. The 2026 PSU Award is contingent on achieving specific market conditions and outperforming the Russell 2000 Index over a four-year performance period.

Management Comments

• "We invite you to participate in the Annual Meeting of Shareholders of USANA Health Sciences, Inc. on Wednesday, May 20, 2026, at 11:00 AM, Mountain Daylight Time."
• "We are pleased to provide access to our proxy materials over the Internet under the U.S. Securities and Exchange Commissions notice and access rules."
• "Continuing to employ this distribution process will conserve natural resources and reduce the costs of printing and distributing our proxy materials."
• "Your vote is important to us and I do hope you will vote as soon as possible."
• "We believe that our executives and employees, as well as the compensation programs that incent them, are key factors in driving strong financial and operational performance and creating shareholder value."
• "The Compensation Committee believes that those results generally affirm shareholder support of our approach to executive compensation."
• "We are confident that these initiatives will lay the foundation for the Company to generate long-term growth."
• "The Board has determined that having Mr. Guest serve as Chief Executive Officer and Chairman is appropriate and in the best interest of the Company based on Mr. Guests experience, vision, leadership and deep knowledge of the Company and all of its stakeholders."

Industry Context

StockSavvy.ai notes that USANA's focus on an omnichannel strategy and enhancements to its Brand Partner compensation plan reflect broader industry trends in the direct selling and health and wellness sectors, which are adapting to evolving consumer preferences and digital engagement models. The acquisition of Hiya Health Products also signals a strategic move to diversify revenue streams beyond core nutritional offerings.

Comparison to Industry Standards

• The Compensation Peer Group for USANA includes companies like Herbalife, Ltd., Nu Skin Enterprises, Inc., and Medifast, Inc., which are publicly traded direct selling and nutritional companies. This allows for benchmarking of executive compensation against direct competitors.
• The Performance Peer Group, also including companies like Herbalife, Nu Skin, and Medifast, is used to assess operating performance relative to direct competitors in the direct selling space.
• The company's executive compensation targets are generally set around the 50th to 75th percentile of its Compensation Peer Group.
• The company's total shareholder return (TSR) is compared against the Russell 2000 Index and a peer group of direct selling companies (Nu Skin Enterprises, Herbalife Nutrition, LifeVantage Corporation, Medifast, Inc., Natures Sunshine Products, Inc., and Mannatech, Inc.) for the Pay versus Performance analysis.

Management Changes

Corporate Governance

Related Party Transactions

• The company was not a party to any related party transactions in 2025 that required disclosure.
• The Audit Committee reviews and approves any related party transactions, ensuring they are fair and reasonable to USANA and comparable to arm's-length dealings.

Stakeholder Impact

• Shareholders: The election of directors, ratification of auditors, and advisory vote on executive compensation directly impact shareholder governance and oversight. Stock ownership requirements aim to align shareholder and management interests.
• Employees: Executive compensation programs are designed to attract, retain, and motivate executives, with a pay-for-performance philosophy. General employees benefit from standard insurance and 401(k) plans.
• Management: Executive compensation is structured with base salary, short-term incentives, and long-term equity awards, with specific targets and caps. The CEO pay ratio highlights the significant compensation difference between the CEO and the median employee.
• Auditors (KPMG): The company seeks shareholder ratification for KPMG's reappointment as independent registered public accounting firm for Fiscal Year 2026, with fees for FY2025 totaling $3,690,237.

Next Steps

• Shareholders are encouraged to vote their shares for the upcoming Annual Meeting.
• The company will continue to advance initiatives in 2026, including aligning costs with sales and enhancing the Brand Partner compensation plan.
• The company will continue to execute its diversification strategy towards an omnichannel model.
• The 2026 PSU Award will be evaluated based on market conditions and performance over the next four years.
• Final voting results will be filed with the SEC in a Form 8-K within four business days following the Annual Meeting.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting. While it details standard corporate governance practices and proposals, it does not contain significant new financial performance data or strategic shifts that would warrant a strong buy or sell recommendation. The mixed financial results (growth in consolidated sales offset by a decline in core nutritional sales) and the conditional nature of future incentive payouts suggest a 'hold' position pending further operational developments.

Keywords

USANA Health Sciences, Annual Meeting, Proxy Statement, Shareholder Meeting, Director Election, Executive Compensation, KPMG, Virtual Meeting, Corporate Governance, SEC Filing